banner news

Singapore, February 22, 2019 – Credo Diagnostics Biomedical Pte. Ltd., a groundbreaking molecular diagnostic company, has been selected to participate in the Animal Health Investment Europe Forum. The company is one of the 12 finalists that have been selected to compete for the Animal Health Innovation Award for 2019.


Animal Health Investment Europe is a premier international investment forum dedicated to showcasing to investors the most innovative emerging animal health companies. During the Innovation Showcase emerging and pre-revenue organizations will pitch their company in front of a room of investors.


“The QubeMDx is truly a breakthrough for the animal health sector and for diagnostics in general, finally bringing PCR to the point-of-care.” said Stephen Kao, CEO of Credo Diagnostics Biomedical. “We are very excited to take the stage in London and have the opportunity to introduce our revolutionary solution to European investors and industry experts.”


Credo Diagnostics Biomedical’s presentation will begin at 11:50 a.m. on Tuesday, February 26th and will be held at etc Venues in London.


About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics Biomedical develops, and manufactures innovative, cost-effective, and rapid Molecular Diagnostic solutions at the Point-of-Care (POC) in the areas of Animal Health, Human Health, and Human Wellness. By providing the right information, at the right time, and to the right people, we can improve the lives of billions of people and animals around the world.



We at Credo Diagnostics Biomedical pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.